<DOC>
	<DOCNO>NCT02197286</DOCNO>
	<brief_summary>A ten week , blind trial vitamin D vs. placebo 80 patient schizophrenia schizoaffective disorder low blood level vitamin D elevate blood level amino acid proline . The aim study evaluate anticipate clinical response vitamin D supplementation include negative symptom cognitive deficit , evaluate safety vitamin D supplementation schizophrenia patient evaluate relationship change plasma proline level efficacy outcomes .</brief_summary>
	<brief_title>Targeted Vitamin D Treatment Schizophrenia-Associated Hyperprolinemia</brief_title>
	<detailed_description>25-hydroxyvitamin D ( vitD ) insufficiency associate cognitive decline long-been consider important schizophrenia susceptibility . VitD supplementation suggest at-risk , recent study demonstrate vitD insufficiency extend adolescent adult schizophrenia . The mechanism vitD deficits confers risk unknown . However , vitD transcriptional regulator , investigator recently find vitD significantly up-regulates PRODH gene expression . This important high know genetic risk schizophrenia confer hemizygous microdeletion chromosome 22q11 , PRODH map . Furthermore , PRODH encode proline oxidase , catalyze proline catabolism . Proline neuromodulator glutamatergic synapsis , peripheral hyperprolinemia associate learning memory deficit neurotransmitter dysregulation animal model , human , decrease intelligence quotient ( IQ ) , cognitive impairment , schizoaffective disorder . The investigator recently find &gt; 25 % schizophrenia patient hyperprolinemic hypothesize causal relationship vitD , proline elevation , schizophrenia , vitD insufficiency cause decrease PRODH expression hyperprolinemia . Measuring fast plasma 25hydroxyvitD proline 64 patient 90 control , investigator find vitD insufficiency ( &lt; 30ng/ml ) significantly associate schizophrenia ( OR:2.1 , p=0.044 ) , vitD level negatively correlate proline ( p=0.01 ) , vitD insufficient subject three time great odds hyperprolinemia ( p=0.046 ) . Moreover , demonstrate hyperprolinemia explains &gt; 37 % association vitD insufficiency schizophrenia , signify vitD insufficiency increase schizophrenia risk , least part elevate proline . These finding advocate target schizophrenia-associated hyperprolinemia alleviate vitD insufficiency , may improve symptom include neurocognitive deficit . The Specific Aims study : Aim 1 ) To Evaluate clinical response vitamin D3 ( vitD3 ) treatment , target patient vitD insufficiency hyperprolinemia . Aim 2 ) To Evaluate relationship fast plasma proline change , PRODH expression , symptom , development efficacy biomarker . The aim accomplish via ten week , double-blind , placebo control trial , schizophrenia schizoaffective disorder subject vitD insufficient hyperprolinemic , randomize vitD3 ( 4,000 international unit ( IU ) /day n=40 ) placebo ( n=40 ) adjunct antipsychotic .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Inclusion Criteria Recruitment 1 . Male Female , racial/ethnic group , age 1865 year . 2 . Admission diagnosis schizophrenia , schizophreniform disorder , schizoaffective disorder . 3 . Capability give inform consent . Inclusion Criteria Randomization Trial Entry 1 . Fasting hyperprolinemia ( define 2 standard deviation ( SDs ) genderadjusted mean measured historical control : 203.3 micromolar ( uM ) females 327.6 uM male ) . 2 . 25 ( OH ) D insufficiency ( &lt; 30ng/ml ) . 3 . Confirmed diagnosis schizophreniform disorder , schizophrenia schizoaffective disorder . Exclusion Criteria Recruitment 1 . Organic brain disorder . 2 . Valproate treatment within 14 day , know proline upregulatory effect . 3 . Pregnant woman woman childbearing potential , surgicallysterile use appropriate method birth control . 4 . Amino acid metabolism disorder diagnosis . 5 . Hypercalcemia ( &gt; 10.4mg/dL ) , hypercalciuria ( &gt; 0.20mg/mg ) , hyperthyroidism ( &gt; 65pg/ml ) history renal stone , kidney disease , atherosclerosis , sarcoidosis , histoplasmosis lymphoma . 6 . Chart record HIV positive status . 7 . Treatment clozapine , may reflect general treatment resistance . Exclusion Criteria Randomization Trial Entry 1 . Abnormal serum/ urine metabolic lab value suggest hypercalcemia ( serum Calcium &gt; 10.4mg/dL ) , hypercalciuria ( urine calcium/urine creatinine &gt; 0.20 mg/mg ) , hyperthyroidism ( parathyroid hormone ( PTH ) &gt; 65pg/ml ) . 2 . Initiation Valproate treatment . 3 . Continued use dietary supplementation , fish oil supplementation vitamin D supplement ( &gt; 400 IU/day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>